AI co-scientist startup CTO on 'hypothesis slop,' deterministic code and the goal of compressing a century of science into a decade (opens in new tab)

In the span of several weeks this spring, every major frontier AI lab and cloud hyperscaler formally declared pharma R&D a core vertical. In April, OpenAI launched GPT-Rosalind, its frontier reasoning model series built for life sciences research, biology, and drug discovery. The ChatGPT developer also announced a significant partnership with Novo Nordisk that same…